Byrne P, Cullinan J, Smith S. Statins for primary prevention of cardiovascular disease. BMJ 2019;367:16 de octubre. [Ref.ID 103197]

McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, Belohlávek J, Böhm M, Chiang C-E, Chopra VK, de Boer RA, Desai AS, Diez M, Drozdz J, Dukát A, Ge J, Howlett JG, Katova T, Kitakaze M, Ljungman CEA, Merkely B, Nicolau JC, O'Meara E, Petrie MC, Vinh PN, Schou M, Tereschchenko S, Verma S, Held C, DeMets DL, Docherty KF, Jhund PS, Bengtsson O, Sjöstrand M, Langkilde A-M, for the DAPA-HF Trial Committees and Investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019:19 de septiembre. [Ref.ID 103194]

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S, COMPASS Investigators. Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial. Gastroenterology 2019;157:agosto. [Ref.ID 103177]

Korol S, White M, O'Meara E, Rouleau JL, White-Guay B, Dorais M, Ahmed A, de Denus S, Perreault S. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?. Eur J Clin Pharmacol 2019;75:837-47. [Ref.ID 103176]

Thayakaran R, Adderley NJ, Sainsbury C, Torlinska B, Sumilo D, Thomas GN, Toulis KA, Nirantharakumar K. Thyroid replacement therapy, thyroid stimulating hormone concentrations, and long term health outcomes in patients with hypothyroidism: longitudinal study. BMJ 2019;366:3 de septiembre. [Ref.ID 103172]

Garmendia CA, Gorra LN, Rodríguez AL, Trepka MJ, Veledar E, Madhivanan P. Evaluation of the inclusion of studies identified by the FDA as having falsified data in the results of meta-analyses. The example of the apixaban trials. JAMA Intern Med 2019;179:4 de marzo. [Ref.ID 103094]

Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. JAMA Surgery 2019:24 de abril. [Ref.ID 103091]

Akyea RK, Kai J, Qureshi N, Iyen B, Weng SF. Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease. Heart 2019:15 de abril. [Ref.ID 103087]

Anónimo. FDA approves new treatment for osteoporosis in postmenopausal women at high risk of fracture. U.S. Food and Drug Administration 2019:9 de abril. [Ref.ID 103084]

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

Pinto T. Los nuevos anticoagulantes obligan a las farmacéuticas a pagar cientos de millones para evitar juicios . eldiario.es 2019:31 de marzo. [Ref.ID 103065]

Zheng SL, Roddick AJ. Association of aspirin use for primary prevention with cardiovascular events and bleeding events. A systematic review and meta-analysis. JAMA 2019;321:22 de enero. [Ref.ID 103021]

Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:2 de febrero. [Ref.ID 103016]

Chao TF, Chiang CE, Chen TJ, Lip GYH, Chen SA. Reassessment of risk for stroke during follow-up of patients with atrial fibrillation. Ann Intern Med 2019:1 de enero. [Ref.ID 102996]

Manson JE, Cook NR, Lee I-M, Christen W, Bassuk SS, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE, for the VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med 2019;380:3 de enero. [Ref.ID 102995]

Ortiz de Landaluce L, Carbonell P, Asensio C, Escoda N, López P, Laporte JR. Gabapentin and pregabalin and risk of atrial fibrillation in the elderly: a population-based cohort study in an electronic prescription database. Drug Saf 2018;41:diciembre. [Ref.ID 102913]

Modin D, Jorgensen ME, Gislason S, Jensen JS, Kober L, Claggett B, Hegde SM, Solomon SD, Torp-Pedersen C, Biering-Sorensen T. Influenza vaccine in heart failure cumulative number of vaccinations, frequency, timing, and survival: a Danish nationwide cohort study. Circulation 2018;139:10 de diciembre. [Ref.ID 102908]

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, Groeneveld PW. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008-2016. JAMA Intern Med 2018;178:julio. [Ref.ID 102882]

Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]

Ray WA, Chung CP, Murray KT, Smalley WE, Daugherty JR, Dupont WD, Stein M. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018;320:4 de diciembre. [Ref.ID 102867]